240-B), and 40 ng/mL Recombinant Mouse IL-6 (Catalog #
406-ML), then stained with Rat Anti-Mouse IL-17F Monoclonal Antibody (Catalog # MAB2057, filled histogram) or isotype control antibody (Catalog #
MAB006, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')
2Secondary Antibody (Catalog #
F0105B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_lightbox">

240-B), and 40 ng/mL Recombinant Mouse IL-6 (Catalog #
406-ML), then stained with Rat Anti-Mouse IL-17F Monoclonal Antibody (Catalog # MAB2057, filled histogram) or isotype control antibody (Catalog #
MAB006, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')
2Secondary Antibody (Catalog #
F0105B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." alt="Mouse splenocytes were treated for 24 hr with 50 ng/mL PMA, 200 ng/mL Ca
2+ionomycin, 10 ng/mL Recombinant Human TGF-beta (Catalog #
240-B), and 40 ng/mL Recombinant Mouse IL-6 (Catalog #
406-ML), then stained with Rat Anti-Mouse IL-17F Monoclonal Antibody (Catalog # MAB2057, filled histogram) or isotype control antibody (Catalog #
MAB006, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG F(ab')
2Secondary Antibody (Catalog #
F0105B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin." class="big_thumb" />